Advanced searches left 3/3

Esophageal Cancer - ClinicalTrials.gov

Summarized by Plex Scholar
Last Updated: 13 May 2022

* If you want to update the article please login/register

Esophageal Cancer Genetics Studies

Esophageal cancer is China's fourth most common cause of cancer death in China and the seventh most common cause of cancer deaths worldwide. Evidence pointing to the existence of Mendelian inheritance in high-risk Chinese populations suggests that there is an association of positive family history with elevated risk, evidence of familial aggregation of cases, and segregation studies suggesting Mendelian inheritance in high-risk families. A tumor/non-tumor research will be conducted in Taiyuan, where a bio specimen bank consisting of samples from hundreds of cases of esophageal, gastric cardia, and gastric body cancers will be created. In a limited number of cases, high-density genome-wide scans with microsatellite markers will be used to find potential hot spots in additional tumor/non-tumor samples, as well as further testing of these hot spots and other candidate markers. Blood samples for DNA from hundreds of healthy people from high-risk and low-risk areas will be collected in second and second stages to determine potential population differences in polymorphisms for particular genomic markers. A family research will be conducted on the esophagus, cardia, and/or stomach area of stomach cancers in families with 2 or more cases of cancer-associated with cancer.

Source link: https://clinicaltrials.gov/ct2/show/NCT00341276


Early Detection of Esophageal Cancer

Although several HPV-related cancers have been identified, several HPV-associated cancers have been reported, HPV's role in esophageal carcinogenesis remains unclear. HPV incidence in ESCC in Henan province, which is in the central Asian esophageal cancer belt and of which Linxian is a component, has ranged from 0-78%. Given the potential for cancer prevention by using the vaccine if HPV is present, it is imperative to determine whether HPV is or is not involved in ESCC in Linxian. We will 1 determine the prevalence of HPV DNA in ESCC tumors and 2 analyze HPV DNA in HPV DNA-positive cases. HPV DNA will also be tested for the presence of HPV DNA in nontumor specimens, and serum will be tested for HPV 16 and HPV 18 E6/E7 seropositivity as a marker of HPV-associated cancer.

Source link: https://clinicaltrials.gov/ct2/show/NCT00341523


The Golestan Cohort Study of Esophageal Cancer

Esophageal cancer is the sixth most common cause of cancer death worldwide, killing over 380,000 people each year. Over 80% of esophageal cancers occur in developing countries, where the overwhelming majority of cases are squamous cell carcinomas. Esophageal cancer is characterized by a geographically diverse epidemic. The Central Asian Esophageal Cancer Belt, one of Central Asia's most prominent high-risk region, stretches from the Caspian Sea to northern China and includes focus areas with greater incidence rates in both genders of greater than 100/10s/year. D CEG investigators have investigated esophageal and gastric cancer in one of these extremely high-risk areas, Linxian, China, at the eastern end of the Belt for the past 20 years. At the other end of the high-risk Belt, we now have the opportunity to perform similar experiments in another of these very high risk zones, Golestan Province, Iran. Golestan people, a regionally, culturally, and ethnically distinct from Linxian, are geographically, ethnically, and ethnically distinct, with only in their extraordinary high incidences of esophageal cancer. Both countries' research shows that doing similar research in these two unusual populations will increase our chances of finding key new modifiable risk factors for esophageal cancer in both countries. Our cohort study is a joint effort between the Digestive Disease Research Center of Tehran University of Medical Sciences, the International Agency for Research on Cancer, and DCEG.

Source link: https://clinicaltrials.gov/ct2/show/NCT00450788


Molecular Epidemiology of Esophageal Cancer: Pilot Project

OBJECTIVES: Investigate the role of many genetically linked variables in combination with cigarette smoking and diet in the etiology and prevention of esophageal cancer. OUTLINE: Blood and tumor tissue samples are obtained. A total of 1,000 tissue samples from patients and healthy volunteers will be collected for this research.

Source link: https://clinicaltrials.gov/ct2/show/NCT01035398


Phase IIB Randomized Trial of Proton Beam Therapy Versus Intensity-Modulated Radiation Therapy for the Treatment of Esophageal Cancer

Study Results: If you are deemed eligible to enroll in this research, you will be randomly assigned to one of two study groups: If you are in Group 1 or Group 1, you will receive IMRT. Up to 28 treatments will be administered by radiation therapy 1 time a day, 5 days a week. While you are receiving radiation therapy, your doctor may decide that it is in your best interest to also receive chemotherapy. Study Visits: Before starting radiation therapy, you will have a baseline visit. You will also complete the symptom and quality of life questionnaires. If you are getting radiation therapy, you will soon have a study visit every week. The Length of Study: You will be treated with radiation therapy for up to 28 treatments. The following tests and procedures will be performed about 4-6 weeks after you stop receiving radiation therapy: Your medical history will be documented. If your doctor agrees it is in your best interest after you have undergone radiation therapy, you will have surgery to remove the tumor. As part of this research, the researcher will monitor you for side effects and pain after the surgery. Even if you do not return to MD Anderson for follow-up visits after undergoing esophageal cancer treatment, you may be asked by the study staff to inquire about your wellbeing.

Source link: https://clinicaltrials.gov/ct2/show/NCT01512589


Neoadjuvant Immunotherapy Combined With Neoadjuvant Chemotherapy for Locally Advanced Esophageal Cancer: an Open Label, Randomized Control, Phase II Trial

Immunocheckpoint inhibitors can induce tumor formation. This research is intended to conduct a controlled, open-label, phase II clinical trial to determine the effectiveness and safety of neoadjuvant immunotherapy with neoadjuvant chemotherapy in a locally advanced esophageal squamous cell carcinoma patient with PD-L1 positive.

Source link: https://clinicaltrials.gov/ct2/show/NCT04625543


A Randomized Study of the Efficacy and Safety of OncoGelâ„¢ Treatment as an Adjunctive Therapy to Systemic Chemotherapy and Concurrent External Beam Radiation Prior to Surgery in Subjects With Localized or Loco-regional Esophageal Cancer

OncoGel has been shown in combination with standard chemotherapy and radiation therapy in patients with previously untreated, resectable, local or local-regional adenosarcoma or squamous cell carcinoma. The primary aim of this research is to determine the safety of OncoGel in combination with standard chemotherapy and radiation therapy in patients with previously untreated, resectable, local or local-regional adenosarcoma or squamous cell carcinoma. Both patients will be offered IV cisplatin on Day 1 and Day 29 and IV 5-FU are administered continuously for 96 hours beginning on Day 1 and Day 29. All patients will now be treated with out-patient radiation therapy for 28 treatments twice a day for 5 1/2 weeks, beginning on Day 1. Patients randomized to the OncoGel treatment program will have the OncoGel drug injected into their esophageal tumors during an endoscopic procedure right before starting systemic chemotherapy and radiation therapy. Both patients will have CT scans for tumor measurements before beginning chemotherapy and 12 weeks later after completion of the radiation therapy and both cycles of chemotherapy.

Source link: https://clinicaltrials.gov/ct2/show/NCT00573131


A Phase Ib/II, Open-Label, Multicenter, Randomized, Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)

In this research, two cohorts of patients with gastric cancer who have progressed after receiving a platinum-containing or fluoropyrimide-containing chemotherapy regimen in the first-line setting, and the first-line Gastric Cancer Cohort includes patients with gastric cancer with no prior chemotherapy. In each cohort, eligible patients will be randomized to one of several treatment arms. In addition, a cohort of patients with esophageal cancer who haven't undergone prior systemic therapy for their disease will be included in this study.

Source link: https://clinicaltrials.gov/ct2/show/NCT03281369


Pathological Response Prediction to Neo-adjuvant Chemoradiotherapy in Esophageal Carcinoma and Comparison of Engineered Features Versus Deep Learning Models

The current care for esophageal carcinoma, neoadjuvant concurrent chemo-radiotherapy, followed by surgery is the current standard of care, and ample evidence has backed the assertion that complete pathological response is a positive prognostic marker for improved outcomes. Predicting the likelihood of obtaining pCR prior to neoadjuvant therapy may lead to the modification of therapeutic protocols for those patients that are unlikely to achieve pCR. Radiomics is a recent entrant in the field of imaging where precise features are derived from the intensity and distribution pattern of pixels based on a region-of-interest based on a region-of-interest. Due to the multi-dimensional nature of data extracted using radiomics, Artificial Intelligence techniques are especially useful for analyzing and predicting radiomic features. Both Machine Learning and Deep Learning [utilising Convolutional Neural Networks] are both part of the AI framework. Using radiomics-based ML and AI-based modeling, our aim is to determine pCR prevalence in our study population.

Source link: https://clinicaltrials.gov/ct2/show/NCT04489368

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions